|6/19/2017 9:51 AM|
See attached for Policy Bulletin 17-01
|6/19/2017 9:45 AM|
|5/31/2017 3:01 PM|
|5/22/2017 3:49 PM|
Today the Department of Drug and Alcohol Programs (DDAP) announced the official go-live for the new DDAP Data System (PA WITS).
You can stream / download today’s webcast using the links below:
Additional information on PA WITS including: Training, policy bulletin and the Business Associated-Qualified Service Organization Agreement (a.k.a. BAQSOA or QSOA) providers must enter into with FEi can be found at
Signed BAQSOAs should be returned to FEi, Inc at:
• Fax: 410-715-6538
Once FEi receives the agreement, they will activate all of the users for that agency based on the list of user accounts the provider compiled for DDAP several months ago. Users will get an automated email to set up their account.
|5/22/2017 8:54 AM|
Providers' Clinical Support System for Medication Assisted Treatment (PCSS-MAT) today launched its free 24-hour course specifically developed for nurse practitioners (NPs) and physician assistants (PAs) to treat opioid use disorder (OUD).
PCSS-MAT is jointly providing the course with continuing education by the American Psychiatric Nurses Association (APNA) and American Academy of PAs (AAPA).
The 24 hours of coursework, mandated by the Comprehensive Addiction and Recovery Act (CARA), is broken up into
1. an eight-hour MAT waiver training and
2. 16 hours of training for treating OUD
Once the 24 hours of training are completed, NPs and PAs may apply to SAMHSA for a waiver to prescribe buprenorphine, one of three FDA-approved medications for the treatment of OUD.
Download instructions and information.
The American Psychiatric Nurses Association is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of 05/17/2017.
This program has been reviewed and is approved for a maximum of 16.00 AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of 05/17/2017.
|5/17/2017 12:58 PM|
The Department of Drug and Alcohol
Programs (DDAP) is excited to announce the official go-live for the new DDAP Data System (PA WITS) on May
22, 2017. This version of the PA WITS system is being implemented
two-months ahead of schedule for the purposes of collecting TEDS data since
September 1, 2015.
We invite you to join a live streaming
webcast to kick-off the first day of your access to PA WITS. The webcast
will be presented by DDAP project leaders covering important topics
including: policy requirements, e-Training, and how to gain access.
The webcast will be recorded and available for viewing at a later date.
|5/17/2017 9:24 AM|
Please click the link for the Licensing Alert Information Bulletin 2017-01 for Urinalysis Testing.
|4/26/2017 11:21 AM|
A PA Advisory Council on Drug and Alcohol
Abuse subcommittee is compiling information on the availability of free
grief support groups statewide that are specifically
tailored for parents, siblings, spouses, etc. that have lost a loved
one to addiction. If you are aware of any such groups, please send the
information to Council member Jennifer Zampogna at email@example.com.
|4/14/2017 9:58 AM|
Centers for Medicare and Medicaid Services (CMS) is hosting a webinar entitled
“Introduction to the American Society of Addiction Medicine (ASAM) Criteria for
Clinical and Program Standards.” The webinar will provide an overview of the
substance use disorder treatment care continuum and standards described in the
American Society of Addiction Medicine (ASAM) Criteria. The webinar will
provide an overview of all the ASAM Criteria levels of care, and then focus
specifically on complex levels of care, including withdrawal management, early
intervention, partial hospitalization, and clinically managed low-intensity
residential services. The webinar will be held on Wednesday, April 19th
from 3:30pm– 5:00pm EST.
for the webinar here.
|4/12/2017 8:19 AM|
In preparing for the statewide transition from the
Pennsylvania Client Placement Criteria (PCPC) to the American Society of
Addiction Medicine (ASAM) Criteria, DDAP has prepared the attached list of
Frequently Asked Questions which is also available on its website at the
following location: http://www.ddap.pa.gov/treatment/Pages/ASAM_FAQ.aspx
. Additional questions that are not currently addressed by the FAQ can be
submitted to RA-DATREATMENT@pa.gov
and updates will be made to the website on a regular basis.
|4/6/2017 2:43 PM|
The new toolkit of fliers, posters, brochures, Web ads, and other materials that are typically made available to help advertise the DEA’s National Prescription Drug Take-Back Day is now live at https://www.dea.gov/take-back/takeback-news.shtml. The material is under the “Partnership Toolbox” button on the right-hand side.
Please feel free to pass this info along to your partnering organizations in drug abuse prevention so they can use these toolkit items, push them out to others, and help spread the word about the upcoming take-back day on April 29.
|3/22/2017 10:43 AM|
Commonwealth Prevention Alliance Conference Registration NOW OPEN!!
The 27th Annual Commonwealth Prevention Alliance “Leading the Challenge” Prevention Conference brochure is now available to download, view and print from the CPA website. Please view the brochure for detailed information prior to going to the online registration site. Payments may be made by credit card or check.
The Pennsylvania Commission on Crime and Delinquency is once again offering up to 50 scholarships to this year’s conference. The scholarship application process will only be open from March 20th through April 15th at 11:59 p.m. Applicants for this need-based scholarship will be notified no later than May 12 of the result. No one already registered for this year’s conference is eligible to apply. For more detailed information on all eligibility requirements, please check the CPA website.
Also available on the CPA website are the following:
• Nomination forms for the Maggie Marcopul Award for Service to the Prevention Field Award. Deadline: April 14th
• Applications for the PA Coalition of the Year Award. Intent to Apply Deadline: April 19, Application Deadline: May 12th
• Application information for youth groups to apply for the Youth Conference and Rally. Deadline: April 20th
And finally, it is now easier to apply for CPA membership through the new online membership registration program. CPA members receive a significant discount on this year’s conference. Membership payments can be made online with most major credit cards or by mailing in your check. Check out the Membership page on CPA’s website for more details. A listing of current members may be viewed there.
CPA Website Address: www.commonwealthpreventionalliance.org
|3/16/2017 7:16 AM|
DDAP has, in consultation with the Governor’s Policy Office and the Office of General Counsel, weighed our options for continuing the use of our PCPC (Pennsylvania Client Placement Criteria) tool for determining the appropriate level of care for an individual seeking treatment or already within our treatment system. After weighing the options, we have decided that the benefits of using a customized tool no longer exceed the benefits of using the nationally recognized ASAM (American Society of Addiction Medicine) tool. One reason for the transition stems from the Centers for Medicare & Medicaid Services (CMS) Medicaid Managed Care Final Rule that was issued last summer, which will limit federal reimbursement for residential treatment of Medicaid recipients to 15 days. In response to that rule, and specifically the provision related to the IMD exclusion, Pennsylvania aims to better position ourselves in submitting a 1115 waiver to CMS related to the IMD exclusion. The 1115 waiver application requires the use of the ASAM tool. This issue surrounding the IMD exclusion is not the only reason for making the change, however. The newly acquired treatment data system is already equipped with the ASAM continuum of care which will make this new system more usable with fewer modifications, which limits the risk of future system maintenance issues. Additionally, because the ASAM is currently utilized for placement decisions related to adolescents, and by many commercial insurance providers for both adults as well as adolescents, converting to this tool will create consistency for providers and payers across the treatment system.
While there are multiple advantages to this conversion, we understand that it will not come without its challenges. We have a team of employees who are currently in the process of establishing a strategic plan for transitioning from the PCPC to the ASAM and will be gathering input from stakeholders and establish a workable process that moves us to the use of the ASAM over time, with the goal of full implementation occurring by July 2018. I will continue to keep you posted on the progress and impacts of this effort. I would ask that this become a standing agenda item in our meetings with your membership.
|3/7/2017 12:08 PM|
PreventSuicidePA and the Pennsylvania Garrett Lee Smith Youth Suicide Prevention in Schools and Colleges Grant are excited to announce the dates for our annual Suicide Prevention at the Ballpark nights. This year there will be three games across the Commonwealth, and a portion of the proceeds from each ticket purchased through the links below will go to suicide prevention in Pennsylvania. A printable flyer that includes information for all three games is attached. Dates and ticket information can be found by clicking on the following links:
June 9 – Harrisburg (Senators host Binghamton). Ticket information coming soon
|1/18/2017 10:19 AM|
|12/22/2016 9:44 AM|
The Pennsylvania Department of Drug and Alcohol Programs’ FY 2017 Annual Synar Report is currently available for review on the agency’s website: http://www.ddap.pa.gov/Pages/Annual-Reports.aspx . This report is submitted to SAMHSA as a requirement of the Substance Abuse Block Grant and provides information about initiatives aimed at decreasing youth access to tobacco.
In addition to the DDAP website, this report along with the full SAPT Block Grant Application, is available on WebBGAS. To access the block grant reports, log in as "citizenpa" and use "citizen" as your password. Comments can be made at: http://www.ddap.pa.gov/Pages/Contact_Request_Form.aspx
|11/22/2016 9:54 AM|
The Pennsylvania Department of Drug and Alcohol Programs (DDAP) has been absent a data solution to gather and report Treatment Episode Data System (TEDS) information to the Substance Abuse and Mental Health Services Administration (SAMSHA) since September of 2015. DDAP also recognized the need to secure a system to replace its legacy prevention data collection system. DDAP is excited to announce that the agency, along with its partners in the Department of Health, Bureau of Informatics and Information Technology and the Department of Administration, Office of Information Technology, has completed its evaluation of data systems and awarded the new contract to FEi Systems, Inc. to provide their proven Web Infrastructure for Treatment Services (WITS) solution. FEi is a leading health IT, services, and analysis organization, specializing in healthcare solutions for federal, state, and local governments. For the past decade, FEi has been at the forefront of the industry in its primary areas of expertise—behavioral health data systems and IT solutions, long term services and supports software solutions, and health IT for federal and state clients.
The data system selected, WITS, is a web-based application that has been in production since 2003, when the pilot customers Iowa, Alaska and Salt Lake County, Utah, began using the system to collect clinical and TEDS data for reporting. Since that time, the solution is currently in use by 30 states and counties for a wide variety of clinical, contract, billing, and case management services. DDAP will join the WITS User Group (WUG) that will enable coordination, collaboration and cost sharing among the other states using the WITS solution. The WITS solution will provide SCAs, Providers and DDAP with a single integrated system to collect Treatment and Prevention data that satisfies mandatory government reporting requirements for the planning, administration, and monitoring of Behavioral Health Treatment Programs, Prevention Programs, and Federal Grant Management programs.
The implementation and rollout of the WITS data system will be clearly communicated with all stakeholders. DDAP is working with FEi Systems to develop a timeline for implementation and we will provide updates as soon as they are available.
Thank you all for the outstanding services provided to our clients!
|10/26/2016 3:30 PM|
DEPARTMENT OF DRUG AND ALCOHOL PROGRAMS ANNOUNCES:
FREE DOWNLOADABLE MEDIA LITERACY CURRICULA
(MIDDLE AND HIGH SCHOOL)
The Department of Drug and Alcohol Programs is pleased to announce that it is making available free, downloadable educational curricula to prevention providers and educators for the purpose of teaching digital and media literacy to middle and high-school students.
The “Media Straight Up! Critical Thinking Skills for Pennsylvania’s Youth” (middle school level) and “Pushing Back: Responding to Representation of Drugs and Alcohol in Popular Culture” (high school level) are curricula that provide specific instructional strategies for raising young people’s awareness and critical thinking skills in responding to mass and social media messages that depict alcohol, tobacco, prescription and illegal drug use. Digital and media literacy skills help students to evaluate the quality and accuracy of what they see, hear and read. They help them recognize how and why media messages appeal to their audience, sharpening awareness of unstated but implied messages.
These media literacy curricula are a resource for any prevention specialist or educator to teach youth about the important skills of digital and media literacy which can contribute to a young person’s ability to understand how media messages affect their perceptions of drugs and alcohol, and may influence the choices they make. Prevention specialists, teachers, school counselors, and community leaders can each play a role in promoting critical thinking to our students about the unhealthy messages they hear and see daily throughout today’s media.
|8/22/2016 10:47 AM|
The Pennsylvania Gaming Control Board has launched a multi-faceted public service campaign to warn youth and parents about the dangers of attempting to gamble at a PA casino when underage. Feel free to disseminate this information on your website, social media sites, etc.
The campaign is titled “What’s Really at Stake” and is designed to raise awareness among youth that it is illegal to gain access to a casino floor in Pennsylvania under the age of 21, convey the numerous consequences of underage gambling, and demonstrate the link between underage gambling and other negative behaviors.
Additionally, the campaign provides messages to parents and friends who all too often facilitate gambling by an underager.
All funding for the What’s Really at Stake campaign is derived from confiscated winnings of voluntary or involuntary excluded patrons who illegally entered a Pennsylvania casino, gained winnings, and were caught in the facility.
|8/5/2016 1:21 PM|
Department of Drug and Alcohol Programs (DDAP) has released an innovative tool
to identify available treatment beds for individuals in residential treatment
programs. For more information or to register, you can visit the PA Open Beds page
on our website or email RA-DAOPENBEDS@pa.gov
or call Dan Miller at 717-736-7466.
|8/5/2016 1:20 PM|
DDAP wishes to make our stakeholders
and the general public aware of two discount opportunities for the individual
purchase of naloxone with a prescription or through the use of the Pennsylvania
Physician General’s Standing Order:
the manufacturer of the “Evzio” naloxone auto-injector has announced that they
will minimize the out-of-pocket cost to patients and their family members and
caregivers by providing commercially-insured patients filing a prescription for
EVZIO with an out-of-pocket cost of less than $20 or, in most cases, $0, even
if their commercial insurance plan does not cover EVZIO. This reduced
price is through a pharmacy discount. Additional information about this
reduced price can be found at:
the manufacturer of Narcan Nasal Spray, has partnered with CVS Pharmacy to
offer individuals without insurance a $35 discount coupon available through the
local CVS pharmacy.
requests that this information be shared at large so that individuals are made
aware of these opportunities for obtaining naloxone at a reduced cost.
(Note: DDAP requests that
pharmaceutical companies or pharmacy discount programs notify the Department of
any additional price discounts as they become available so that they can be
added to this announcement.)
|8/4/2016 2:42 PM|
The Department of Drug and Alcohol Programs (DDAP) is
concerned about the rise in hepatitis C cases in Pennsylvania (PA),
particularly among persons who inject drugs (IDU). The Centers for
Disease Control and Prevention recommends hepatitis C virus (HCV) testing for
those who currently inject any type of drug (Opioids, Methamphetamine, Cocaine,
etc.) or have injected drugs in the past, including those who injected once or
a few times many years ago. PA has experienced a dramatic increase in
hepatitis C infections in individuals with injection opioid and/or heroin
addiction who are 18 to 35 years of age. DDAP recommends that all
licensed drug and alcohol addiction treatment facilities perform a risk assessment
for HCV and refer to medical or community based providers for necessary
screening/testing as appropriate.
Because many individuals you serve are at high risk for hepatitis C, you play
an important role in combating this public health issue. If you have
current practices that you believe are effective in combating this disease, we
would appreciate you sharing these with us so we can promote them across the
field. Please send this information to Justin White at firstname.lastname@example.org.
Through improved identification and treatment of individuals with hepatitis C,
we can begin to reduce the spread of this disease. Please remember to
obtain consumer consent and maintain confidentiality when sharing test results
with the consumers’ primary care physicians or other physical health
specialists involved in hepatitis treatment. In some cases, you may be
able to utilize a Qualified Service Organization Agreement (QSOA) to permit the
exchange of patient identifying information. If you have questions about
when this is possible, please contact our Division of Licensing Director,
Treldon Johnson, at email@example.com.
For more information regarding hepatitis C testing of IDU clientele, please
Charles Howsare, MD, MPH
Viral Hepatitis Prevention Coordinator
PA Department of Health
Thank you for your critical assistance in controlling hepatitis C in PA.
Contact Person: Justin White
|6/22/2016 7:42 AM|
DDAP is currently working with Department of Human Services, Division of Facilities and Property Management to identify locations in the Commonwealth that our Drug and Alcohol provider network might be able to leverage for expansion of services. These locations may be more affordable and require less effort than building a new facility. Current list of available locations is attached. If a provider is interested in seeing the properties available, or would like more information regarding this, please contact Jodi Skiles at firstname.lastname@example.org or 717-736-7454.
|6/22/2016 7:38 AM|
Please be aware of the following communication/commitment from Kaleo Pharmaceutical for individual persons obtaining naloxone via their pharmacy:
Any commercially insured person with a prescription can now quickly obtain EVZIO with an out-of-pocket cost of, in most cases, $0, even if their insurance does not cover EVZIO. To facilitate this, Kaleo Pharmaceutical has a toll free number, 877-4-EVZIO-EZ, that patients, physicians, or pharmacists can use to get immediate assistance to fill this potentially life-saving prescription.
Feel free to share this information with others.
|6/22/2016 7:37 AM|
DDAP and the PA Department of Health have been working closely with the PA Medical Society (PAMED) to support their efforts to create a free Continuing Medical Education (CME) related to “Addressing Pennsylvania's Opioid Crisis: What the Health Care Team Needs to Know.” This CME program is divided into four modules and covers a variety of tools and resources for prescribers and dispensers to better address opioid addiction.
- Opioid Prescribing Guidelines
- Naloxone Prescribing
- Referral to Treatment
- In process: Prescription Drug Monitoring Program called the ACHIEVING BETTER CARE BY MONITORING ALL PRESCRIPTIONS PROGRAM or (ABC-MAP)
PAMED has decided to make ALL their opioid CME’s available at no-cost until the end of the 2016 calendar year. Given the extent of the opioid crisis and the urgent need for physicians and other providers to get up to speed on opioid prescribing guidelines, naloxone, referrals to treatment, and the ABC-MAP Program, PAMED wanted to promote this CME to ALL members of the healthcare team that need it. With that in mind, your group may want to consider doing the same if you are currently charging for the series. The link to PAMED’s CME that is includes the test and certificate for CME credits is:
Also, PAMED is going to be developing a 5th module on “Alternative Treatment of Pain” that will highlight non-opioid medication, OT/PT, complementary medicine, and behavior health approaches to managing chronic, non-cancer pain.
|6/10/2016 12:48 PM|
The Department of Drug and Alcohol Programs (DDAP) has been made aware of concerns regarding the rates established between the Single County Authorities (SCAs) and the non-hospital residential detoxification and rehabilitation treatment facilities. To address this issue, DDAP has convened a comprehensive workgroup to identify solutions for the longer term relative to the process and instruments utilized to determine per diem rates. However, for more immediate resolution concerning rates being negotiated for State Fiscal Year 2016/17, DDAP is initiating a two-phase appeals process that allows providers to appeal to the SCA rate setting authority, and failing a satisfactory outcome, the ability to bring appeal to DDAP. This process also allows the SCAs, should negotiations fail to bring about satisfactory result, the ability to appeal to DDAP for final resolution. Attached to this correspondence is a matrix outlining the process for appeal to be followed by both treatment providers and SCAs, as well as the minimum documentation to be submitted with an appeal. Questions that arise in regards to the appeals process may be directed to the resource account established for this process and denoted on the attachment.
|6/2/2016 10:52 AM|
The Department of Drug and Alcohol Programs (DDAP), along with the PA Department of Health, has created various overdose prevention and response resources including brochures, flyers, posters, etc. These resources are now available for download and reproduction under the Publications page of DDAP’s Document Library.
|5/16/2016 8:23 AM|
The PBPS support line is open Monday through Friday from 9 AM to 5 PM at 1-888-600-4777. It can also be reached via email at email@example.com If you have any comments you would like to pass along regarding your support experience, please note the date and time you contacted the PBPS help desk along with details of your experience and email them to DDAP at RA-DAWORKFLOW@PA.GOV
|5/4/2016 2:39 PM|
The 2015 PAYS County Reports have been posted on the PAYS website and are available for download at www.pays.pa.gov. Select “2015” in the last paragraph on the page and then select “2015 County Reports”.
|4/26/2016 7:57 AM|
Marijuana and Cannabinoids: A Neuroscience Research Summit was convened by the National Institutes of Health, which focused on the neurological and psychiatric effects of marijuana, other cannabinoids, and the endocannabinoid system. Both the adverse and the potential therapeutic effects of the cannabinoid system were discussed. The goal of this summit was to ensure evidence-based information is available to inform practice and policy, particularly important at this time given the rapidly shifting landscape regarding the recreational and medicinal use of marijuana.
This summit was recorded and the archived video recordings of the summit are now available - http://apps1.seiservices.com/nih/mj/2016/VideoCast.aspx.